


Houston Society of Clinical Pathologists 63rd Annual Spring Symposium

CURRENT CONCEPTS IN GYNECOLOGIC PATHOLOGY

7 AMA PRA Category 1 Credits™

SATURDAY, APRIL 27, 2024






Ovarian Epithelial Tumors in Soundbites

Anaís Malpica, M.D. Professor Department of Pathology



Making Cancer History*



2020




- Serous Carcinoma Low Grade High Grade
- Mucinous Carcinoma
- Endometrioid Carcinoma
- Clear Cell Carcinoma
- Others:

Mesonephric-like Carcinoma Malignant Brenner Tumor

Practical Issues


Low-Grade Serous Carcinoma



#1. Uniform cells with mild to moderate cytologic atypia


#2. Usually a low mitotic index (\leq 12 mitoses per 10 HPFs)

Microinvasive Low Grade Serous Carcinoma, WHO 2020




Focus of low-grade serous carcinoma, < 5 mm, desmoplasia

Microinvasive Low Grade Serous Carcinoma, WHO 2020





Focus of low-grade serous carcinoma, < 5 mm, marked epithelial proliferation


Low-Grade Serous Carcinoma, Macropapillae





Low-Grade Serous Carcinoma, Massive Epithelial Growth in Cystic Spaces














Low Grade Serous Ca, Solid Pattern and Clear Cytoplasm






Low-Grade Serous Carcinoma




- Polygonal cells with eosinophilic cytoplasm, nuclear pleomorphism and signet-ring cells
- Low mitotic index
- The tumor has a mesothelioma-like appearance
- IHC:
 - Claudin 4, MOC-31, PAX-8, ER, PR, +
 - Calretinin, thrombomodulin, keratin 5/6, -
 - p53 wild type

Low-Grade Serous Carcinoma

- 20 mitoses per 10 HPFs
- No significant pleomorphism
- p53 wild type







Serous Carcinoma, Tumor Heterogeneity (Low Grade and High Grade)

- Uncommon
- Synchronous or metachronous
- A problem when dealing with limited tissue

Low Grade Serous Cavs. Mesonephric-like Ca




Low Grade Serous Cavs. Mesonephric-like Ca





Low Grade Serous Carcinoma, Recurrence

- Usually, as low grade serous carcinoma
- Rare cases as:
 - Sarcomatoid carcinoma, example below (14 years after initial Dx)
 - Undifferentiated carcinoma
 - Mesonephric-like carcinoma
 - Carcinosarcoma




Mesonephric-like Ca after the Dx of LGSCa






TTF-1+




ER/PR rare cells +



WT-1 -

Mesonephric-like Ca after the Dx of LGSCa, Misinterpreted as High Grade Serous Carcinoma



Low Grade Serous Carcinoma, Rare Associations

Ovarian Primary

• Germline mutations:

- BRCA1/2
- MUTYH
- BAP1
- *RB1*
- *CHEK2*
- *APC*
- FANCA
- Rubinstein-Taybi syndrome

Peritoneal Primary


- BRCA1 mutation
- Lynch syndrome
- PALB2 mutation

Low-Grade Serous Carcinoma, Molecular Findings

- MAPK pathway mutations in $\approx 60\%$ of the cases:
 - KRAS (19%-40%), NRAS (9-26%), and BRAF (2%-16%)
 - Rare, HRAS, NF1, NF2, MAP3K1, and ERBB2
- Other mutations: USP9X, E1F1AX, MACF1, ARID1A, DOT1L, ASH1L, UBR5, PIK3CA, FFAR1, and DNM3

*potential use of mTOR inhibitors

High Grade Serous Carcinoma




Pleomorphic cells with marked nuclear atypia (≥3:1 variation in size and shape) High mitotic index (>12 mitoses per 10 HPFs)


High Grade Serous Ca, Issues


- Using the architecture and not paying attention to the cytology to assign the grade
- Tumor heterogeneity
- A wide variety of patterns and appearances
- Recurrence has a different histotype
 - Carcinosarcoma ---undersampling vs. lack of recognition vs. dedifferentiation
 - Sarcoma –undersampling vs. lack of recognition vs. dedifferentiation
 - Neuroendocrine Ca lack of recognition

Pathologist does not follow diagnostic criteria




High grade serous Ca, interpreted as low grade






Low grade serous Ca, interpreted as high grade

High Grade Serous Ca, Papillary Pattern, Mimicking a Serous Borderline Tumor with a MP




High Grade Serous Ca, Broad Base Papillae (TCC Pattern) and Papillae with Prominent Vessels





High Grade Serous Ca


Solid pattern


Spindle cells

















High Grade Serous Ca




Clear cells







Adenosquamoid appearance





Carcinosarcoma, Initially Interpreted as HGSCa



Mixed Ca, Neuroendocrine Ca and HGSCa, Initially Interpreted as HGSCa








Wild-type, < 10% of cases

Extrauterine High Grade Serous Carcinoma: p53




Nuclear overexpression, without or with cytoplasmic staining

Null phenotype


Cytoplasmic overexpression

Extrauterine High Grade Serous Carcinoma: p16

p16 expression is variable: block, patchy or absent



Low Grade Serous Carcinoma: p16, block expression \approx 7% of cases



p53

Assessment of Folate Receptor Alpha/Folate Receptor 1 Protein (FRα/FOLR1) by IHC


Why?

- To justify the use of mirvetuximab soravtansine (Elahere[™])
 - Antibody-drug conjugate (ADC), comprised of a FRα directed antibody conjugated to a microtubule inhibitor
 - Arrests cell cycle and causes apoptotic cell death
 - November 2022, it received accelerated approval by the USA FDA
 - Treatment of adult patients with FRα positive, platinum-resistant ovarian, fallopian tube or peritoneal cancer who have received 1-3 prior systemic treatment regimens

Assessment of Folate Receptor Alpha/Folate Receptor 1 protein (FRα/FOLR1) by IHC

USA FDA approved Ventana FOLR1 RxDx Assay

≥ 75% of cells with moderate and/or strong membranous staining




Low grade serous carcinoma

Moderate and strong membranous staining Variable staining in <75% of cells

Cytoplasmic staining

Irrelevant findings

Microinvasive Mucinous Carcinoma



- Focus of invasion into the stroma < 5mm in greatest linear extent
- Marked cytologic atypia within the invasive

Microinvasive Mucinous Carcinoma


• Experience is limited

 Rare cases have been reported with recurrences and death


> Nomura K, Aizawa S. Cancer 2000 Khunamornpong S. et al. Int J Gynecol Path 2011 WHO 2014 and 2020

Mucinous Borderline Tumor with Microinvasion

- Focus of invasion into the stroma
 5 mm in greatest linear extent
- Mild to moderate cytologic atypia within the invasive focus




Mucinous Intraepithelial Carcinoma, Marked Atypia of the Epithelium



Invasive Mucinous Carcinoma

Expansile/confluent type


- confluent glandular pattern
- uninterrupted by normal ovarian stroma
- measuring at least 5 mm in linear extent



Invasive Mucinous Carcinoma

Infiltrative type

• Small glands, nests of cells or individual cells infiltrating the stroma in an area measuring at least 5 mm in linear extent



Mucinous Carcinoma


- Intraepithelial Carcinoma
 - Stage I disease, recurrence rate 5%
- Invasive Carcinoma
 - Stage I disease , 5-year survival 91%
 - Advanced stage disease, all patients die of disease
 - Expansile pattern more common than the infiltrative pattern
 - Recurrences in stage I tumors with an expansile pattern tend to be seen in the pelvis
 - Infiltrative invasion appears to be more aggressive than the expansile type

Riopel MA, et al., 1999 Lee KR and Scully R, 2000 Rodriguez IM and Prat J, 2002 Gouy S, et al., 2018

Molecular Alterations in Ovarian Mucinous Carcinoma

Molecular Alteration	Ovarian Mucinous Carcinoma		
MSI-H	22%		
KRAS mutation	43%		
BRAF mutation	0%		
HER2 amplification	18%		
APC or CTNNB1 mutations	9%		
TP53 mutations	26%		

Kelemen LE, Köbel M, 2011




Anaplastic Carcinoma

- Keratin is useful to assess the extent of the tumor or if spindle cells are present
- Pts who present with stage 1A disease tend to have a favorable outcome

Endometrioid Borderline Tumor


- Microinvasion: confluent glandular proliferation < 5 mm in linear extent
- Intraepithelial carcinoma: marked cytologic atypia



Endometrioid Carcinoma


Back-to-back glandular proliferation > 5mm

Intracystic complex papillary growth




Endometrioid Carcinoma

- Confounding histological features:
 - Nuclear disorganization, to exclude high-grade serous carcinoma
 - (WT-1, p53, and p16)
 - Eosinophilic luminal contents, to exclude mesonephric-like carcinoma (ER, PR, GATA-3, and TTF-1)




Endometrioid Carcinoma


• IHC confounding findings: CDX2+ and WT-1+




Endometrioid and Undifferentiated Carcinoma (Dedifferentiated Carcinoma)




Ker 7 rare cells +



Endometrioid Carcinoma with Mucinous Metaplasia




Endometrioid Ca and Poorly Differentiate Squamous Ca




Endometrioid Carcinoma of Ovary


Molecular Subtype	Percentage	Mutation	Percentage
No specific molecular		CTNNB1	53%
profile	69-73%	РІКЗСА	40%
Hypermutated due to mismatch repair deficiency	13%	KRAS	33%
TP53 mutated	9-13%	ARID1A	30%
Ultramutated due to POLE mutations	5%	PTEN	17%

Seromucinous Carcinoma Arising in a Seromucinous Borderline Exists, but It Is a Rare Tumor




Clear Cell Carcinoma






Discrepancy between the degree of atypia and the mitotic index

Clear Cell Carcinoma with Squamous Differentiation




Abundant mucinous material


Sarcomatoid features




Clear Cell Carcinoma and Yolk Sac Tumor



Clear Cell Carcinoma and Yolk Sac Tumor






Clear Cell Carcinoma

Molecular classes, in descending order :

- No specific molecular profile
- *TP53*
- MMRd
- POLE mut


Most common mutations:

- ARID1A, 51%
- PIK3CA, 47%
- TERT promoter, 27%
- *KRAS*, 18%
- *TP53*, 12%
- ATM, 10%
- *PTEN*, 6%
- *POLE*, 4%





• CK7




- PAX-8
- TTF-1


- ER
- PR


- GATA-3
- CD10 (luminal)

p53 wild type, HNF1B can be diffusely + Napsin A and AMACR can be +, but only focally \leq 5% of cells


Endometrioid vs Serous... Think Mesonephric-Like









S.







ORIGINAL ARTICLE



Extrauterine Mesonephric-like Carcinoma A Comprehensive Single Institution Study of 33 Cases

Elizabeth D. Euscher, MD,* Mario L. Marques-Piubelli, MD,* Preetha Ramalingam, MD,* Ignacio Wistuba, MD,* Barrett C. Lawson, MD,* Michael Frumovitz, MD,† and Anais Malpica. MD*

(Am J Surg Pathol 2023;00:000-000)

Pts' age: 37-74 yrs (median, 59 yrs) Advanced stage disease (FIGO III/IV), 13 Sarcomatous differentiation, 2 Associations:

> endometriosis (63%) borderline tumor (21%) part of a mixed Ca (42%)


Misclassified, 42%

Molecular Findings: *Kras>>>Tp53, SPOP, PIK3CA* Metastasis: liver, lung, peritoneum More aggressive than low grade endometrioid Ca

Malignant Brenner Tumor


Molecular Findings

- *PIK3CA* mutations
- *MDM2* amplification




Brenner Tumor

Borderline Brenner Tumor



Malignant Brenner Tumor



West Texas is About the Light



A view from Fort Davis

Marfa

Installation by Robert Irwin, from the West Coast Light and Space Movement